Anomalía de Ebstein: diagnóstico tardío en un adulto con cirrosis hepática de etiología multifactorial
Ebstein's anomaly: Late diagnosis in an adult with multifactorial liver cirrhosis
DOI:
https://doi.org/10.37910/RDP.2026.15.3.e482Keywords:
Ebstein anomaly, Tricuspid valve insufficiency, Liver cirrhosis, Atrial fibrillationAbstract
Introduction: Ebstein's anomaly (EA) is a rare congenital heart disease (<1 %), characterized by apical displacement of the tricuspid valve, resulting in severe tricuspid regurgitation (TR). Its presentation in the fourth decade of life is exceptional. Case report: A 41-year-old male with a history of HBV/HCV infection, intravenous substance use, and tricuspid endocarditis in 2009, was admitted due to refractory ascites, anasarca, and progressive dyspnea. Imaging studies revealed massive TR due to previously undiagnosed EA, portal hypertension due to multifactorial cirrhosis (congestive, viral, and toxic), and paroxysmal atrial fibrillation (PAF). Discussion: EA, silent for decades, decompensated upon the appearance of PAF and sepsis. Cirrhosis is not exclusively viral/toxic; chronic venous congestion due to severe TR significantly contributed to liver damage (congestive hepatopathy), evidenced by a VExUS grade III score and disproportionate cholestasis. Management of PAF posed a dilemma: although CHA₂DS₂-VASc 2 indicates anticoagulation, bleeding risk due to esophageal varices in Child-Pugh C (HAS-BLED 2) contraindicates it, opting for rate control with carvedilol, which also reduces portal pressure. Conclusion: EA should be considered in the differential diagnosis of unexplained right heart failure in young adults. In every patient with chronic liver disease showing an atypical or diuretic-refractory course, systematic echocardiographic evaluation is indicated to rule out an underlying congestive cardiac cause. Management requires a multidisciplinary approach (cardiology, gastroenterology, infectious diseases).
References
1. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(12):e81-e192.
2. Attenhofer Jost CH, Connolly HM, Dearani JA, Edwards WD, Danielson GK. Ebstein's anomaly. Circulation. 2007;115(2):277-285.
3. Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart Failure and Liver Disease: Cardiohepatic Interactions. JACC Heart Fail. 2019;7(2):87-97.
4. Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: a review of pathophysiology and clinical relevance. J Clin Exp Hepatol. 2016;6(3):229-239.
5. Elmaghawry M, Rizk HH, Almaghraby A. Ebstein anomaly and infective endocarditis: a dangerous combination. Echocardiography. 2018;35(9):1472-1474.
6. Beaubien SW, Rola P, Haycock K, Bouchard J, Lamarche Y, Spiegel R, et al. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound (VExUS) grading system. Cardiovasc Ultrasound. 2020;18(1):16.
7. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
8. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.
9. Lee S, Lee H, Lee JS, Kim TH, Uhm JS, Joung B, et al. Anticoagulation in patients with liver cirrhosis and atrial fibrillation: a systematic review and meta-analysis. Thromb Haemost. 2020;120(5):783-793.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Guillermo Blanco, Oscar Genie, Yosman Marval, Victoria Rosenschein, Andrés Sánchez

This work is licensed under a Creative Commons Attribution 4.0 International License.
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y construir a partir del material
- para cualquier propósito, incluso comercialmente.
Bajo los siguientes términos:
-
Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.







